- Home
- BGR vs CERS Comparison
BGR vs CERS Comparison
Compare BGR & CERS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- BGR
- CERS
- Stock Information
- Founded
- BGR 2004
- CERS 1991
- Country
- BGR United States
- CERS United States
- Employees
- BGR N/A
- CERS N/A
- Industry
- BGR Trusts Except Educational Religious and Charitable
- CERS EDP Services
- Sector
- BGR Finance
- CERS Technology
- Exchange
- BGR Nasdaq
- CERS Nasdaq
- Market Cap
- BGR 321.9M
- CERS 347.3M
- IPO Year
- BGR N/A
- CERS 1997
- Fundamental
- Price
- BGR $12.77
- CERS $1.31
- Analyst Decision
- BGR
- CERS Strong Buy
- Analyst Count
- BGR 0
- CERS 2
- Target Price
- BGR N/A
- CERS $3.50
- AVG Volume (30 Days)
- BGR 73.3K
- CERS 997.9K
- Earning Date
- BGR 01-01-0001
- CERS 05-01-2025
- Dividend Yield
- BGR 6.02%
- CERS N/A
- EPS Growth
- BGR N/A
- CERS N/A
- EPS
- BGR 0.69
- CERS N/A
- Revenue
- BGR N/A
- CERS $185,144,000.00
- Revenue This Year
- BGR N/A
- CERS $25.57
- Revenue Next Year
- BGR N/A
- CERS $10.54
- P/E Ratio
- BGR $18.97
- CERS N/A
- Revenue Growth
- BGR N/A
- CERS 13.06
- 52 Week Low
- BGR $11.38
- CERS $1.12
- 52 Week High
- BGR $13.37
- CERS $2.54
- Technical
- Relative Strength Index (RSI)
- BGR 56.91
- CERS 47.05
- Support Level
- BGR $12.29
- CERS $1.28
- Resistance Level
- BGR $12.64
- CERS $1.38
- Average True Range (ATR)
- BGR 0.20
- CERS 0.07
- MACD
- BGR 0.08
- CERS 0.01
- Stochastic Oscillator
- BGR 82.86
- CERS 45.00
About BGR BlackRock Energy and Resources Trust
BlackRock Energy & Resources Trust is a closed-end equity fund providing total return through a combination of current income, gains and capital appreciation by investing in equity securities and derivatives of energy and natural resources companies. The fund invests in various sectors such as information technology, financials, healthcare, consumer discretionary, industrial, energy, materials and utilities.
About CERS Cerus Corporation
Cerus Corp is a biomedical products company focused on the field of blood transfusion safety. The INTERCEPT Blood System is designed to reduce the risk of transfusion-transmitted infections by inactivating a broad range of pathogens such as viruses, bacteria, and parasites. The company sells its INTERCEPT platelet and plasma systems in the United States of America, Europe, the Commonwealth of Independent States countries, the Middle East, and selected countries in other regions around the world. The firm continues to operate in only one segment: Blood safety and generates revenue from the same.